Stock ARGX ARGENX SE
Add to a list
To use this feature you must be a member
Log inSign up

All News argenx SE

Equities

ARGX

NL0010832176

Real-time Euronext Bruxelles
Other stock markets
 06:39:29 2024-04-30 am EDT 		5-day change 1st Jan Change
350.4 EUR +0.55% Intraday chart for argenx SE +0.34% +2.01%
Apr. 17 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Apr. 16 Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
MT
Argenx : argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
PU
Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
GL
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading
MT
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
AQ
Argenx : argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
PU
Argenx : argenx Announces Annual General Meeting of Shareholders on May 7, 2024
PU
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GL
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
CI
Argenx Announces Annual General Meeting of Shareholders on May 7, 2024
GL
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating
MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia
MT
Argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
GL
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia
CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
MT
US Futures, European Stocks Rise After Fed Maintains Outlook
DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading
MT
Argenx : argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
PU
Argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARGX Stock
  4. News argenx SE